Results From Phase 3 Guselkumab PsA Trials Announced
Janssen announced positive top-line results from two phase 3 trials of Tremfya (guselkumab) in patients with moderate to severe psoriatic arthritis.
Dermatological Disorders
Does PPI Use Increase the Risk of Gynecomastia?
According to the results of a retrospective cohort study, male patients who utilize proton pump inhibitors (PPIs) appear to be at increased risk of developing gynecomastia.
Next post in Gastroenterology Information Center
